Currently, licogliflozin (LIK066) is the only SGLT1/2 inhibitor being evaluated in NASH independent of T2DM presence, alone and in combination with the FXR agonist tropifexor, in the ongoing phase 2 ELIVATE study (NCT04065841). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.